SPEX Stock Overview
Spexis AG, a clinical-stage biopharmaceutical company, engages in discovering, developing, in-licensing, and acquiring molecules for rare diseases and cancer.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Spexis AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF0.058 |
| 52 Week High | CHF1.06 |
| 52 Week Low | CHF0.012 |
| Beta | -0.14 |
| 1 Month Change | -25.19% |
| 3 Month Change | -87.03% |
| 1 Year Change | -86.25% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -97.20% |
Recent News & Updates
Recent updates
Shareholder Returns
| SPEX | CH Biotechs | CH Market | |
|---|---|---|---|
| 7D | -9.7% | -3.1% | -0.9% |
| 1Y | -86.3% | 11.6% | -4.0% |
Return vs Industry: SPEX underperformed the Swiss Biotechs industry which returned 11.6% over the past year.
Return vs Market: SPEX underperformed the Swiss Market which returned -4% over the past year.
Price Volatility
| SPEX volatility | |
|---|---|
| SPEX Average Weekly Movement | 25.5% |
| Biotechs Industry Average Movement | 7.5% |
| Market Average Movement | 3.5% |
| 10% most volatile stocks in CH Market | 7.4% |
| 10% least volatile stocks in CH Market | 1.9% |
Stable Share Price: SPEX's share price has been volatile over the past 3 months.
Volatility Over Time: SPEX's weekly volatility has decreased from 35% to 26% over the past year, but is still higher than 75% of Swiss stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 28 | Jeff Wager | spexisbio.com |
Spexis AG, a clinical-stage biopharmaceutical company, engages in discovering, developing, in-licensing, and acquiring molecules for rare diseases and cancer. Its products pipeline includes ColiFin, an inhaled colistimethate sodium product that is in the phase 3 trial for the treatment of cystic fibrosis (CF) infections; Inhaled Murepavadin, a novel class inhaled antibiotic which is in the phase 1 development stage to treat Pseudomonas aeruginosa infection in people with CF; EBX-002 for non-tuberculous mycobacterial lung infections; Balixafortide for oncology and non-oncology indications; New CXCR4 for treating orphan and hematological malignancies, and non-oncology indications; and Outer Membrane Protein Targeting Antibiotic BamA and lipopolysaccharide transport protein A programs. Spexis AG is headquartered in Allschwil, Switzerland.
Spexis AG Fundamentals Summary
| SPEX fundamental statistics | |
|---|---|
| Market cap | CHF3.90m |
| Earnings (TTM) | -CHF12.49m |
| Revenue (TTM) | CHF1.17m |
3.3x
P/S Ratio-0.3x
P/E RatioIs SPEX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SPEX income statement (TTM) | |
|---|---|
| Revenue | CHF1.17m |
| Cost of Revenue | CHF0 |
| Gross Profit | CHF1.17m |
| Other Expenses | CHF13.66m |
| Earnings | -CHF12.49m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.18 |
| Gross Margin | 100.00% |
| Net Profit Margin | -1,068.71% |
| Debt/Equity Ratio | 23.4% |
How did SPEX perform over the long term?
See historical performance and comparison